News Releases

June 2020

June 15, 2020 6/15/2020 Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders

June 12, 2020 6/12/2020 Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

June 12, 2020 6/12/2020 Basic Agreement on a Comprehensive Collaboration Between Takeda and MC-UBS Realty for the Operation of the Shonan iPark

June 11, 2020 6/11/2020 Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD

June 11, 2020 6/11/2020 Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

June 6, 2020 6/6/2020 New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO (lanadelumab) in Reducing Hereditary Angioedema Attacks

May 2020

May 29, 2020 5/29/2020 Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML

May 29, 2020 5/29/2020 Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS

May 29, 2020 5/29/2020 Takeda Receives Positive CHMP Opinion for Pre-filled Syringe Presentation of TAKHZYRO® (lanadelumab) for use as a Preventive Treatment for Hereditary Angioedema Attacks

・For Shire news releases, click here